\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

Jul 17, 2012

Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Jul 2, 2012

Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer

Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
Jun 24, 2012

Trovagene to be Added to Russell Microcap Index
Jun 13, 2012

Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
Jun 6, 2012

Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia

Show per page